Technology evaluation: HIVAC-1e.
Bristol-Myers Squibb is developing a vaccine, HIVAC-1e, comprised of a recombinant vaccinia virus expressing the HIV-1 gp160 envelope glycoprotein. The vaccine has potential for the treatment of HIV and other viral infections and has entered phase I trials [135333]. In an initial phase I trial, 11 vaccinia-naïve volunteers were vaccinated with HIVAC-1e, followed by a booster with baculovirus-derived gp160 (VaxSyn). Two weeks after boosting, all 11 volunteers developed HIV-1 specific IgG, with titers of 1:40 to 1:1280 [195287]. Using the same strategy in 29 vaccinia-naïve volunteers, priming with HIVAC-1e was demonstrated as a key determinant of the epitope specificity and magnitude of antibody responses to gp160 [195278].
Zheng
R
R
St Bartholomew's Hospital, Dept of Immunology, University of London, 38 Little Britain, London, UK. r.q.zheng@mds.qmw.ac.uk
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D000818:Animals; D001709:Biotechnology; D019302:HIV Envelope Protein gp160 / Q000235:genetics / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000628:therapy; D006801:Humans; D051379:Mice; D012449:Safety; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D014616:Vaccinia virus / Q000235:genetics
D016915:AIDS Vaccines; D019302:HIV Envelope Protein gp160; D019444:Vaccines, DNA